Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCTNASDAQ:BLUEOTCMKTS:CSLLYNYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$13.64+0.1%$12.47$8.04▼$25.88$369.78M2.27419,503 shs172,653 shsBLUEbluebird bio$4.97$4.69$3.20▼$28.60$48.67M0.27444,431 shsN/ACSLLYCSL$79.96+1.0%$78.96$70.22▼$109.00$77.43B0.7973,133 shs24,766 shsNVSNovartis$121.90-1.5%$115.08$96.06▼$124.45$257.50B0.591.58 million shs955,240 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics0.00%+2.29%+6.61%+50.00%-36.43%BLUEbluebird bio0.00%0.00%0.00%+4.19%-73.09%CSLLYCSL0.00%+3.76%+1.27%+9.01%-20.99%NVSNovartis0.00%+1.33%+3.29%+18.44%+12.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics3.7599 of 5 stars4.62.00.00.03.22.50.6BLUEbluebird bio2.1099 of 5 stars3.10.00.00.01.41.71.3CSLLYCSL0.9562 of 5 stars0.03.01.70.01.20.01.3NVSNovartis1.6386 of 5 stars1.03.02.50.02.70.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.11Buy$54.00296.04% UpsideBLUEbluebird bio 2.25Hold$44.60797.38% UpsideCSLLYCSL 4.00Strong BuyN/AN/ANVSNovartis 2.00Hold$123.671.45% UpsideCurrent Analyst Ratings BreakdownLatest CSLLY, NVS, BLUE, and ARCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.005/28/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$32.005/14/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.005/13/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$68.00 ➝ $66.004/15/2025NVSNovartisBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/10/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$152.31M2.43N/AN/A$8.90 per share1.53BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CSLLYCSL$14.80B5.23$3.98 per share20.10$20.07 per share3.98NVSNovartis$50.32B5.12$10.70 per share11.39$21.59 per share5.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)CSLLYCSL$2.64BN/A0.0019.551.73N/AN/AN/A8/19/2025 (Estimated)NVSNovartis$11.94B$6.4019.0513.841.6824.70%39.44%16.43%7/17/2025 (Estimated)Latest CSLLY, NVS, BLUE, and ARCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025ARCTArcturus Therapeutics-$1.11N/AN/AN/A$17.64 millionN/A7/17/2025Q2 2025NVSNovartis$2.37N/AN/AN/A$13.94 billionN/A5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million4/29/2025Q1 2025NVSNovartis$2.12$2.28+$0.16$1.83$12.92 billion$13.23 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ACSLLYCSL$1.201.50%N/AN/AN/ANVSNovartis$2.602.13%N/A40.63%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus Therapeutics0.065.645.64BLUEbluebird bio0.370.510.33CSLLYCSL0.451.860.85NVSNovartis0.560.790.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%BLUEbluebird bio87.43%CSLLYCSL0.03%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics15.30%BLUEbluebird bio1.40%CSLLYCSLN/ANVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.12 million22.97 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCSLLYCSL32,698968.42 millionN/ANot OptionableNVSNovartis75,8832.11 billion2.11 billionOptionableCSLLY, NVS, BLUE, and ARCT HeadlinesRecent News About These CompaniesNovartis (NYSE:NVS) vs. Roche (OTCMKTS:RHHBY) Head to Head Analysis3 hours ago | americanbankingnews.comDeutsche Bank Reaffirms Their Buy Rating on Novartis AG (NOVN)July 6 at 5:37 PM | theglobeandmail.comWorld Investment Advisors Raises Holdings in Novartis AG (NYSE:NVS)July 6 at 6:48 AM | marketbeat.comNovartis AG (NYSE:NVS) Given Consensus Recommendation of "Hold" by BrokeragesJuly 6 at 2:16 AM | marketbeat.comCatalyst Capital Advisors LLC Increases Holdings in Novartis AG (NYSE:NVS)July 4 at 8:38 AM | marketbeat.comTimber Creek Capital Management LLC Sells 5,799 Shares of Novartis AG (NYSE:NVS)July 4 at 8:15 AM | marketbeat.comDavidson Trust Co. Sells 5,771 Shares of Novartis AG (NYSE:NVS)July 4 at 6:25 AM | marketbeat.comNovartis AG (NYSE:NVS) Shares Sold by Principal Financial Group Inc.July 4 at 5:56 AM | marketbeat.comAllspring Global Investments Holdings LLC Purchases 14,057 Shares of Novartis AG (NYSE:NVS)July 4 at 4:05 AM | marketbeat.comNovartis announces top-line results from phase III GCAptAIN study of Cosentyx in giant cell arteritisJuly 3, 2025 | pharmabiz.comPNovartis’ hopes dashed for GCA indication for blockbusterJuly 3, 2025 | thepharmaletter.comTLate-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune ConditionJuly 3, 2025 | biospace.comBNovartis drug flunks phase 3 test in giant cell arteritisJuly 3, 2025 | pharmaphorum.comPNovartis fails in late-stage trial for Cosentyx in giant cell arteritisJuly 3, 2025 | msn.comNovartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns BullishJuly 3, 2025 | msn.comNovartis' Cosentyx Misses Primary Goal in Arteritis Phase III StudyJuly 3, 2025 | zacks.comD.A. Davidson & CO. Sells 65,251 Shares of Novartis AG (NYSE:NVS)July 3, 2025 | marketbeat.comRossby Financial LCC Makes New $288,000 Investment in Novartis AG (NYSE:NVS)July 3, 2025 | marketbeat.comNovartis drug Cosentyx fails late-stage trial for artery diseaseJuly 3, 2025 | reuters.comNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)July 3, 2025 | prnewswire.comNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)July 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeOuster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesBy Leo Miller | June 14, 2025View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones3 Tech Focused ETFs to Watch as the Market Nears All-Time HighsBy Ryan Hasson | June 11, 2025View 3 Tech Focused ETFs to Watch as the Market Nears All-Time Highs5 High-Yielding ETFs to Buy and Hold ForeverBy Ryan Hasson | June 30, 2025View 5 High-Yielding ETFs to Buy and Hold ForeverCSLLY, NVS, BLUE, and ARCT Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$13.64 +0.02 (+0.11%) Closing price 07/3/2025 03:11 PM EasternExtended Trading$13.25 -0.39 (-2.82%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.bluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.CSL OTCMKTS:CSLLY$79.96 +0.78 (+0.99%) As of 07/3/2025 12:58 PM EasternCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Novartis NYSE:NVS$121.90 -1.91 (-1.54%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$122.70 +0.80 (+0.66%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
